152 related articles for article (PubMed ID: 11512313)
21. Cyclosporine withdrawal improves long-term graft survival in renal transplantation.
Gallagher M; Jardine M; Perkovic V; Cass A; McDonald S; Petrie J; Eris J
Transplantation; 2009 Jun; 87(12):1877-83. PubMed ID: 19543068
[TBL] [Abstract][Full Text] [Related]
22. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
23. The natural history of renal function following orthotopic heart transplant.
Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
[TBL] [Abstract][Full Text] [Related]
24. A long-term study on hyperlipidemia in stable renal transplant recipients.
Tse KC; Lam MF; Yip PS; Li FK; Lai KN; Chan TM
Clin Transplant; 2004 Jun; 18(3):274-80. PubMed ID: 15142048
[TBL] [Abstract][Full Text] [Related]
25. Retrospective study of the effects of cyclosporine in comparison with azathioprine on renal transplant recipients infected with hepatitis C virus.
Ichikawa Y; Kishikawa H; Nishimura K; Tokugawa S; Yoshioka I; Arichi N; Fujii N; Kyo M; Nishikawa M
Transplant Proc; 2006 Dec; 38(10):3451-3. PubMed ID: 17175300
[TBL] [Abstract][Full Text] [Related]
26. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment.
Montagnino G; Lorca E; Tarantino A; Bencini P; Aroldi A; Cesana B; Braga M; Lonati F; Ponticelli C
Clin Transplant; 1996 Oct; 10(5):461-9. PubMed ID: 8930463
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
28. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors for development of malignant neoplasia after feline renal transplantation and cyclosporine-based immunosuppression.
Schmiedt CW; Grimes JA; Holzman G; McAnulty JF
Vet Comp Oncol; 2009 Mar; 7(1):45-53. PubMed ID: 19222830
[TBL] [Abstract][Full Text] [Related]
30. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
31. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
[TBL] [Abstract][Full Text] [Related]
32. High body mass index and posttransplant weight gain are not risk factors for kidney graft and patient outcome.
Marcén R; Fernández A; Pascual J; Teruel JL; Villafruela JJ; Rodriguez N; Martins J; Burgos FJ; Ortuño J
Transplant Proc; 2007 Sep; 39(7):2205-7. PubMed ID: 17889138
[TBL] [Abstract][Full Text] [Related]
33. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
34. Oral health in renal transplant recipients administered cyclosporin A or tacrolimus.
Spolidorio LC; Spolidorio DM; Massucato EM; Neppelenbroek KH; Campanha NH; Sanches MH
Oral Dis; 2006 May; 12(3):309-14. PubMed ID: 16700742
[TBL] [Abstract][Full Text] [Related]
35. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
Vivarelli M; Cucchetti A; Piscaglia F; La Barba G; Bolondi L; Cavallari A; Pinna AD
Liver Transpl; 2005 May; 11(5):497-503. PubMed ID: 15838913
[TBL] [Abstract][Full Text] [Related]
36. Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant.
Mourad G; Karras A; Kamar N; Garrigue V; Legendre C; Lefrançois N; Charpentier B; Bourbigot B; Pouteil-Noble C; Bayle F; Lebranchu Y; Mariat C; Le Meur Y; Kessler M; Moulin B; Ducloux D; Delahousse M; Lang P; Merville P; Chaouche-Teyara K; Rostaing L;
Clin Transplant; 2007; 21(3):295-300. PubMed ID: 17488375
[TBL] [Abstract][Full Text] [Related]
37. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
[TBL] [Abstract][Full Text] [Related]
38. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.
Montagnino G; Sandrini S; Casciani C; Schena FP; Carmellini M; Civati G; Rigotti P; Cossu M; Altieri P; Salvadori M; Federico S; Stefoni S; Cambi V; Albertazzi A; Buoncristiani U; Berloco P; Segoloni G; Boschiero L; Sparacino V; Donati D; Turello E; Dal Canton A; Ponticelli C
Transplant Proc; 2005 Mar; 37(2):788-90. PubMed ID: 15848532
[TBL] [Abstract][Full Text] [Related]
39. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients.
Sommerer C; Hartschuh W; Enk A; Meuer S; Zeier M; Giese T
Clin Transplant; 2008; 22(5):549-54. PubMed ID: 18394001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
